Pre-made Secukinumab biosimilar ( Whole mAb, anti-IL17A therapeutic antibody) - benchmark reference antibody
Cat No.: GMP-Bios-ab-510
Anti-IL17A therapeutic antibody (Pre-made Secukinumab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Secukinumab, sold under the brand name Cosentyx, is a human IgG1κ monoclonal antibody that binds to the protein interleukin (IL)-17A, and is marketed by Novartis for the treatment of psoriasis, ankylosing spondylitis, and psoriatic arthritis. It inhibits a member of the cytokine family, interleukin 17A.
Delivery impact due to the Coronavirus Outbreak
With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Anti-IL17A therapeutic antibody (Pre-made Secukinumab biosimilar,Whole mAb)|
|Highest_Clin_Trial (Jan '20)||Approved|
|100% SI Structure||6wio:AB/6wir:AB|
|99% SI Structure||None|
|95-98% SI Structure||None|
|Companies||Beth Israel Deaconess Medical Center;GWT-TUD GmbH;Icahn School of Medicine at Mount Sinai;Novartis;Alcon|
|Conditions Approved||Ankylosing spondylitis;Plaque psoriasis;Psoriatic arthritis;Pustular psoriasis|
|Conditions Active||Hidradenitis suppurativa;Juvenile rheumatoid arthritis;Non-radiographic axial spondyloarthritis;Rheumatoid arthritis;Alopecia areata;Atopic dermatitis;Giant cell arteritis;Necrobiosis lipoidica;Tendon injuries|
|Conditions Discontinued||Asthma;Crohn's disease;Dry eyes;Multiple sclerosis;Polymyalgia rheumatica;Type 1 diabetes mellitus;Uveitis|
|Development Tech||Abgenix XenoMouse|